Randomized control study of the use of faropenem for treating patients with pulmonary tuberculosis

• Published in: International journal of infectious diseases Vol. 132; pp. 99 - 107
• Main Authors: Shangguan, Yanwan, Guo, Wanru, Feng, Xuewen, Shi, Yunzhen, Li, Xiaomeng, Pan, Zhifen, Hu, Ming, Shi, Jichan, Ding, Cheng, Xia, Jiafeng, Hu, Wenjuan, Ji, Zhongkang, Zhao, Chengjie, Li, Yuecui, He, Zebao, Jin, Lingxiao, Tao, Xiaodong, Zhu, Xinming, Zhang, Xiaoqiang, Song, Qun, Zhu, Yuyin, Zheng, Lin, Jin, Xiuyuan, Huang, Shujuan, Jiang, Liangxiu, Wang, Yuping, Wu, Tiantian, Cao, Dan, Zhang, Ying, Li, Lanjuan, Xu, Kaijin
• Format: Journal Article
• Language: English
• Published: Canada Elsevier Ltd 01.07.2023; Elsevier
• Subjects: Antitubercular Agents; Drug Therapy, Combination; Ethambutol - therapeutic use; Faropenem; Humans; Treatment; Treatment Outcome; Tuberculosis; Tuberculosis, Pulmonary - diagnosis; Tuberculosis, Pulmonary - drug therapy; Tuberculosis; Treatment; Faropenem

•Faropenem has been proven useful in replacing ethambutol in the standard regimen.•Faropenem regimen showed a similar treatment success rate to the standard regimen.•Faropenem regimen is well tolerated and has fewer adverse events.•Oral β-lactam antibiotic can be a promising antituberculosis candida...